Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Brovana. Every FDA application for this active ingredient: 1 branded and 17 generic.
As of Nov 21, 2026, FDA lists 18 applications for Arformoterol tartrate (sold as Brovana), first approved Oct 6, 2006, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Arformoterol Tartrate
Part B
$8.5M
−56%
31,771
Arformoterol Tartrate
Part D
$6.3M
+20%
5,838
Brovana
Part D
$112K
−23%
59
Medicaid spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Arformoterol
$2.4M for 25,710 prescriptions, −32% on 2024
Where Medicare prescribes it
20,504 Part D claims in 2024; each state's share of its claims against the national share; see Part D by state
Most, against the national rate
Nebraska 4.2×, Kansas 3.9×, Kentucky 2.5×
Least
Florida 0.4×, California 0.7×, Pennsylvania 0.9×
What pharmacies pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Arformoterol 15 mcg/2 mL soln: $0.640 per mLGeneric · −10% in a year
How its trials ended
5 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Completed, result not reported360%Completed, result not reportedCount3Share60%
Met its primary endpoint120%Met its primary endpointCount1Share20%
Stopped: other or unclear120%Stopped: other or unclearCount1Share20%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
Product storage error (12), No adverse event (3), Constipation (2), Product dose omission in error (2), Swelling face (1), Off label use (1), Cough (1), Circumstance or information capable of leading to medication error (1), Product dose omission issue (1), Product packaging quantity issue (1)
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA